Neurogene Inc. (NasdaqGM: NGNE)
Health Care · Biotechnology · US
$38.63
+1.68% today · +93.2% 1Y
Neurogene Inc. (NasdaqGM: NGNE) operates in the Biotechnology industry within the Health Care sector. The company is valued at $773.04M and employs 131 people.
Over the last twelve months the share price has gained 93.2%, trading between 15.93 and 43.66.
Tweenvest scores Neurogene Inc. across four factors: quality 29/100. Its strongest factor is quality.
NGNE price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $773.04M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -5.04
- Dividend yield
- —
- Beta (5Y)
- 1.95
- 52-week high
- $43.66
- 52-week low
- $15.93
- Avg volume (3M)
- —
- Shares outstanding
- 20.01M
- Employees
- 131
- Next earnings
- —
About Neurogene Inc.
Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease). The company's operations are based in New York, New York.
- Founded
- 2018
- Listed since
- Mar 7, 2014
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.33 | +1.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.12 | +1.86% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €902.00 | +1.90% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $145.13 | +0.04% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.